← Back to all trials
Terminated
NCT01790594
Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation
Conditions: Simultaneous Kidney and Pancreas Transplantation
Sex: All
Ages: 18 Years – 55 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 46
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Location: University of Alabama at Birmingham Birmingham Alabama
Summary
The purpose of this study is to find out if the drug NULOJIX® (belatacept) will minimize the amount of other anti-rejection medications necessary and thereby reduce the long-term side effects caused by the other medications. The researchers also want to learn more about the safety of this treatment and long term health of transplanted pancreases and kidneys.
Eligibility Criteria
Inclusion Criteria:
* Ability to understand and provide written informed consent;
* Candidate for a primary simultaneous kidney and pancreas allograft with random c-peptide \
Source: ClinicalTrials.gov (NCT01790594). StuddyBuddy aggregates publicly available trial information.
